2018
DOI: 10.14326/abe.7.118
|View full text |Cite
|
Sign up to set email alerts
|

Regulatory Science on AI-based Medical Devices and Systems

Abstract: AI-based medical and healthcare devices and systems have unique characteristics including 1) plasticity causing changes in system performance through learning, and need of creating new concepts about the timing of learning and assignment of responsibilities for risk management; 2) unpredictability of system behavior in response to unknown inputs due to the black box characteristics precluding deductive output prediction; and 3) need of assuring the characteristics of datasets to be used for learning and evalua… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(12 citation statements)
references
References 2 publications
0
12
0
Order By: Relevance
“…This is partly driven by the anticipation that thresholds for clinical implementation of many CAD systems will not be high, due to the fact that most of these systems rely on a 'low risk, high impact' principle, although currently regulatory entities do not necessarily consider AI to be low risk. 32 A spurious algorithm prediction will at worst lead to an additional biopsy, yet the algorithm may detect a cancer that might otherwise have been missed. Furthermore, nearly all CAD systems are now considered as second-readers, merely assisting endoscopists.…”
Section: Recent Advances In Clinical Practicementioning
confidence: 99%
“…This is partly driven by the anticipation that thresholds for clinical implementation of many CAD systems will not be high, due to the fact that most of these systems rely on a 'low risk, high impact' principle, although currently regulatory entities do not necessarily consider AI to be low risk. 32 A spurious algorithm prediction will at worst lead to an additional biopsy, yet the algorithm may detect a cancer that might otherwise have been missed. Furthermore, nearly all CAD systems are now considered as second-readers, merely assisting endoscopists.…”
Section: Recent Advances In Clinical Practicementioning
confidence: 99%
“…In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA), a regulatory body, issued a statement on the science of AI‐assisted medical devices and systems in 2018. In this document, the PMDA classified the risks of using the CAD system into five categories, in which the fifth harbors a risk of treatment failure as a result of the misdiagnosis provided by CAD . Considering this risk stratification and other factors, PMDA requests the applicants to carry out a retrospective or prospective evaluation of the CAD system.…”
Section: Future Directionsmentioning
confidence: 99%
“…In this document, the PMDA classified the risks of using the CAD system into five categories, in which the fifth harbors a risk of treatment failure as a result of the misdiagnosis provided by CAD. 67 Considering this risk stratification and other factors, PMDA requests the applicants to carry out a retrospective or prospective evaluation of the CAD system. Currently, only two CAD systems designed for use with laser-induced fluorescence spectroscopy 54,62 and endocytoscopy [42][43][44][45] are approved by regulatory bodies (WavSTAT4; Pentax Corp., Tokyo, Japan, EndoBRAIN; Cybernet System Corp., Tokyo, Japan), but we expect that much more CAD systems designed for colonoscopy will be approved by regulatory bodies in a few years.…”
Section: Requirement For Regulatory Approval and The Strategy To Addrmentioning
confidence: 99%
“…The hurdle of obtaining approval differs according to countries and role of AI in clinical practice. 80 East et al 81 proposed three roles of CADx for colonoscopy. A second observer, a concurrent observer, or an independent decision maker.…”
Section: Regulatory Approval and Legal Issues A) Regulatory Approvalmentioning
confidence: 99%